Research and Markets has announced the addition of the "Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016" drug pipelines to their offering.
The report provides comprehensive information on the Integrin Alpha 7 (ITGA7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development and features dormant and discontinued projects.
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/vzvk3b/integrin_alpha_7
Related Topics: Oncology Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919005751/en/Business Wire
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.